Regorafenib/TAS-102 gives clinically meaningful DCR in Metastatic CRC
Category: #healthcare  By Akshay Kedari  Date: 2020-01-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regorafenib/TAS-102 gives clinically meaningful DCR in Metastatic CRC

The data from the REMETY phase 1 dose escalation trial, unveiled at the Gastrointestinal Cancers Symposium 2020, reportedly shows that the combination of regorafenib (Stivarga) and oral fluoropyrimidine TAS-102 provided a clinically meaningful DCR in third line treatment of individuals suffering from metastatic colorectal cancer (CRC).

The Regorafenib/TAS-102 combination also showed toxicities that were consistent with either agent’s safety profiles. Out of the 12 trial participants that were treated dose level 1 and dose level 2, seven people attained stable disease after a period of eight weeks, showing a disease control rate of 58.3%.

The investigative team was helmed by Dr Markus H. Moehler, MD, University Medical Center of Johannes Gutenberg University Mainz, Germany.

With more than 12 months of follow up of all participating patients, only six events occurred, and the median overall survival was not reached. The estimated PFS (progression-free survival), based upon the complete analysis of the 12 patients was approximately 3.81 months. At six months, the PFS rate was 0.11, and at 12 months, no PFA was seen after the initiation of regorafenib and TAS.

In one of the six patients that were given doses at level 1, one DLT (dose-limiting toxicity) was observed. Two DLTs were observed in two of the six patients at dose level 2. All the observed DTLs were found to be grade-3 hypertension caused by regorafenib.

During the poster presentation of the trial data, researchers commented that the outcomes indicate a phase II recommended TAS-102 dose of 25 mg/m2 twice daily as well as regorafenib dose of 120 mg daily.

The investigators further added that up until now, the Regorafenib/TAS-102 risk benefit assessment has been positive, considering that the grade-3 hypertension is manageable clinically and that no additional DLT was tracked back to TAS-102.

Overall, 152 adverse events were encountered, however, only five of them were considered serious. Hypertension, decreased neutrophil count, fatigue, diarrhea and nausea were the most common adverse events. 

Source credit: https://www.onclive.com/conference-coverage/gi-2020/regorafenibtas102-induces-clinically-meaningful-dcr-in-refractory-metastatic-crc

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Movistar Chile employs Nokias IMPACT platform for smartwatch services
Movistar Chile employs Nokias IMPACT platform for smartwatch services
By Akshay Kedari

Nokia Corporation, a global leader in 5G, networks, and phones, has reportedly announced that Movist...

Advent to acquire 75% stakes in parcel delivery group Hermes UK
Advent to acquire 75% stakes in parcel delivery group Hermes UK
By Akshay Kedari

The US-based private equity firm Advent International has reportedly announced plans to acquire a ma...

MRI Software buys Housing Partners to strengthen digital offerings
MRI Software buys Housing Partners to strengthen digital offerings
By Akshay Kedari

MRI Software LLC, a leading provider of real estate software applications and hosted solutions, has ...